Sign Out
Mometasone furoate nasal spray suspension has been administered concomitantly with loratadine with no effect on plasma concentrations of loratadine or its major metabolite.
Mometasone furoate is metabolized by CYP3A4. Coadministration with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, cobicistat-containing products) may lead to increased plasma concentrations of corticosteroids and potentially increase the risk for systemic corticosteroid adverse effects. Consider the benefit of coadministration versus the potential risk of systemic corticosteroid effects, in which case patients should be monitored for systemic corticosteroid side effects.
Continue with Google